Heat Shock Proteins (HSPs) are a large family of highly conserved proteins involved in assisting protein folding and unfolding in the cells. HSPs are expressed constitutively as well as inducibly and, interacting with antigen presenting cells, induce the expression of various cytokines and chemokines as well as the maturation and migration of dendritic cells, thus acting themselves as cytokines. HSPchaperoned antigenic peptides are also generated within the tumor cells. Such chaperoned peptides are released in the extra cellular medium with an association of HSPs by cell stress, death or tumor cell lyses. HSP-peptide complexes from extra cellular medium are taken up by antigen presenting cells through CD91 receptor and are represented or cross-presented by their MHC class I molecules for specific anti-tumor immune response. In addition, HSPs expressed on the cell surface of tumor cells stimulate a~T-cells and yO T-cells as well as natural killer (NK) cells that are first-line defense mechanisms. In this manner, HSPs have the ability to stimulate both arms of the effecter mechanism of the immune system. These unique immunological attributes of HSPs are presently becoming the basis for tumor immunotherapy. Tumor-derived HSP-peptide complexes have been demonstrated to serve as anti-tumor vaccines. To date various approaches of vaccination using HSPs have been developed and tested clinically. These HSP-based vaccine approaches can be combined with hyperthermia and CTLA-4 blockade to enhance their anti-tumor potentiality.
and promoting cell recovery (4) .
HSPs comprise of six families, HSPlO, HSP40, HSP60, HSP70, HSP90 and HSP I00, on the basis of their monomeric molecular weight, with each family consisting of at least one member but often more. HSP lOis also designated as a small heat shock protein (sHSP) family containing 9 members. All HSPs are originally acting as molecular chaperones and reside in almost every sub-cellular compartment (Fig. 1) . The transcription of inducible form of HSPs is under the control ofthe heat shock factor (HSF) (5) as well as a variety of physiological processes, such as cell cycle control, proliferation and differentiation (6) (7) . Under normal temperature, HSF 1is phosphorylated (S) and occurs in the cytoplasm. In stress, HSF 1 is reversibly transformed from an inactive monomer to a homotriomer, which has high affinity for DNA, transported to the nucleus and hyperphosphorylated which enhances its transcriptional activity (9) , leading to the transcription of heat shock proteins such as hsp70, hsp27, hsp90 etc.
Dual role ofHSPs as chaperone and cytokines
HSPs are well recognized as chaperones and stimulate the monocyte/macrophages to induce the release of proinflammatory cytokines such as tumor necrosis factor-o (TNF-a), interleukin (lL)-1, IL-6, IL-12 and GM-CSF, making the system more potent against pathogens and malignancies. HSP preparation has been shown to induce the release of nitric oxide (NO) which may signal for apoptosis of infected as well as tumor cells, and C-C chemokines by macrophages, monocytes and dendritic cells (DCs). These chemokines then further induce the recruitment of lymphocytes, especially NK-cells, CTL, macrophages and DCs to the site of the tumor formation. They were also shown to induce the maturation of dendritic cells (pAPC) by up-regulating the expression of MHC-I, MHC-II and various co-stimulatory molecules such as CD40, CD69, CDSI, CDS3, CDS6, etc. (10) (11) (12) . The cytokine effects of HSPs are unique in the sense that it does not require ATP hydrolysis, nor cofactors or protein complex assembly. Due to their dual functions as chaperones and cytokines, these are designated as "chaperokines", which have great implication in tumor immunology. The activation and maturation of DCs by gp96 may be responsible for the gp96-induced tumor immunity by inducing the innate and adaptive immune responses (13) .
The cytokine-like activity of HSPs is mediated via CDl4 and Toll-like receptor (both TLR-2 and TLR-4) complex signal transduction pathway, similar to that oflipopolysaccharides (LPS) (Fig. 2) . The mechanism of SPs in TLR signaling cascade has been discussed and found that, unlike LPS signaling, it is Ca" dependent, activating the transcription of the NFKB gene responsible for this cytokinelike function (14) . CD40 is a co-stimulatory molecule, also recognized as a specific receptor both for microbial HSPs (mHSPs) and human HSPs mediating a cytokine-like effect (15) . CD40 is a glycoprotein and a member ofthe TNF receptor super family, primarily exposed on B-cell, monocytes and DCs (16), on epithelial cells, some cancer cells and activated CDS+T-cells (17) , and it plays an important role in T-cell mediated response. HSP-CD40 interactions were found to stimulate production of the C-C chemokines, CCL3, CCL4 and CCL5, which attract the entire repertoire of immunological cells at the site of inflammation, pathogen invasion and tumor (1S). Thl polarizing cytokines IL-12 and TNF-a, co-stimulatory molecules such as CDSO, CDS3 and CDS6, and MHC are also shown to be produced and up-regulated upon interaction ofHSPs to CD40 (12) . This function is crucial in the sense that the expression of co-stimulatory molecules is directly correlated with the activation, as well as the maturation, of DCs and hence by enhancing antigen presentation with T-cell mediated immune responses. In this manner, HSPs interact not only with TLR2/4, but also with CD40 to mediate and produce tumor specific anti-tumor microenvironment. However, due to similar effects led by TLR2/4 and CD40, it might be argued that CD40 may have effect in the endocytosis and endosome formation of HSPs, which then interact with NH2-terminal of TLR2/4 to go into TLR signaling pathway; an elaborated pathway of CD40 which has yet to be investigated.
The chaperokine functions and mechanism of action ofHSPs are similar to that ofLPS and bacterial lipoprotein. Therefore, it is very important to exclude LPS contamination of HSPs preparations. A minute amount of LPS is sufficient to activate an innate immune system and to release proinflammatory cytokines such as TNFa from murine macrophages (19) . Therefore, recently, it was argued that the cytokine effect of HSPs through TLR2/4 signaling might be the result of contaminants. As HSPs are over-expressed in stress conditions, such as in the case of tumor formation, they are taken as a danger signal by the immune system, therefore, their role in induction of proinflammatory cytokines and the activation and maturation ofDCs must not be ignored and should be taken as a mechanism of homeostasis towards the elimination of tumor cells. In one investigation, HSP70 induction ofTNF-a expression was blocked by a chelator of intracellular calcium, whereas there was no such type of effect on the actions of LPS observed, indicating that LPS action is not dependent on intracellular Ca'<influx (20) . The administration of gp96, but not LPS, generates longlasting (1 week) increased NK-cell activity in adult frogs, as well as the induction of IL-l f3 expression, both in larvae and adults (21) . It is therefore clear that there are cytokine effects led by HSP preparation that might not be completely associated with TLR 2/4 signaling pathway, as the LPS does not give rise to intracellular effects of calcium.
HSPs in antigen presentation
The formation of stable MHC complex capable of presenting antigenic peptides to T-cells depends on their proper folding and assembly in the ER, as well as on the availability of peptide ligands. It is reported that HSPs play a key role in antigen processing (22) , folding and assembly of MHC and MHCpeptide complexes, which holds true for many other proteins. Heat shock proteins bind with great affinity to nascently-formed self-polypeptides or partially folded/unfolded antigenic peptides, which may be tumor antigens (23) bacterial antigens (24) viral antigens (19, 25) minor histocompatibility antigens or "model" antigens (26) , and constitute a part of the ubiquitin-proteasome system (27) . Thus, they are involved in chaperoning products of degradation and translocation of MHC class I subunits with peptide fragments to the ER in association with TAP (Transporter associated with antigen processing) where calnexin promote the assembly (28) . As with calnexin, in mammals, binding protein (BiP) (a member of the HSP70 family that resides in the ER) binds transiently to unassembled subunits thus facilitating their assembly and disassembly from TAP (29) . In ER, the subunits are associated and go into the classical secretory pathway for cell surface expression ( Fig. 3 ). Like MHC I, ER resident HSPs, such as grp94, calnexin and calreticulin, bind to Ii and assist in the formation of complexes. The assembled MHC class II complexes are transported to the Golgi complex and to late endosomes/lysosome, where Ii is degraded and a f3 dimers bind peptide, derived from exogenous antigens, for their cell surface display. By taking the mode of MHC class I and class II assemblage, antigens have two ways of displaying on the cell surface, assisted by molecular chaperones such as heat shock proteins.
The HSPs released after tumor cell death due to necrosis are taken up by antigen presenting cells such as dendritic cells (DCs) and macrophages (M<j» through a receptor CD9l, found in all cells, and are reported to be a common receptor for HSP70, HSP90, grp94 (gp96) and calreticulin (30) . It has been found that the HSPs released from necrotic tumor cells by acid elution are associated with tumor antigen peptide, or even proteins, by virtue of their molecular chaperone function. HSP-CD9l interaction at the cell surface of APCs results in internalization and endocytosis of HSP-associated peptides as HSP-peptide complex (31) . Arnold et al state that the endocytosed HSP-peptide complex (gp96-peptide complex) then enters a non-acidic endosomal compartment (32) , where the processing of associated tumor antigenic peptides take place. Further processing of these peptides requires proteosome in the cytosol (30) . Various proteases and peptidases present in the proteasomal complex degrade the peptides into shorter fragments. These peptides are transported by the TAP dimer through the membrane of the endoplasmic reticulum (ER). A physical association between hsp70 and TAP has been shown (33) which indicates that HSP70 may assist in the transfer of peptides from endosomes to TAP. However, the exact mechanism by which peptides are diffused from endosomes or transported from endosomes to TAP is still unclear. The peptides captured by TAP are transferred to the ER resident HSPs such as gp96 (GRP94) and/or calreticulin and other chaperones including protein disulfide isomerase (34) (35) . However, TAP-independent pathways have also been confirmed by using knockout mice, defective for TAP expression. Arnold et al. (1997) reported that gp96 preparations from TAP-defective cells are unable to prime CTL cells for strong cytolytic immune response for antigens whose presentation is TAP dependent.
Recently, it was reported that peptides entering into ER are further trimmed by gp96 which has amino peptidase activity that cleaves the peptides from the amino-terminal end (36) . In this respect, it is MHC class I which guides the trimming in the ER, perhaps by protecting the octamer and allowing the "overhang" to be acted upon by an amino peptidase such as gp96 (37) . Trimmed peptides go to classical secretory pathway from ER to Golgi body from where they are exocytosed with the formation of secretory vesicle for being represented or crosspresented onto cell surface of APCs by MHC class I molecules. The MHC class I molecules loaded with tumor antigenic peptides then cross-prime CD8+ T cells or CTL cells, resulting in strong, tumor specific anti-tumor immune responses, and consequently facilitating the recognition and eradication of tumor by specific CD8+ T cells on which specific CTL epitopes are generated due to the their cross-priming (38) . It not only mediates cell lysis of tumor cells but also provokes immunological memory so that the organism may become immune to subsequent challenges of tumors from which peptide is derived. In addition, HSPs have the ability to present antigen directly onto the cell surface of non-APCs after chaperoning, or they may be presented directly onto the cell surface through another molecule which has yet to be discovered. It has been reported that this direct presentation led by HSPs/of HSPs are found to elicit powerful maturation signal for DCs (39) . All these accounts of HSPs makes them an important subject of study so that an effective immunotherapeutic protocol can be designed for the future strategy of the treatment of cancer.
The role ofHSPs in immunosurveillance
As the HSPs are the most abundant soluble molecules in the cells or at the site of the tumor, they can be reasonably expected to be the most reliable messenger of cell death which would result if the organism were in stress or in danger such as in the case of tumor progression and invasion.
It has been shown that HSPs released after cell death or necrosis of tumors are able to activate plethora of non-APC such as al3 T cells, yo T cells, (41) ( Fig. 4) . The yo T-cells recognize HSPs expressed on the cell surface of tumor cells and become activated.
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The activated yo T cells lyse the tumor cells
with specificity, which further stimulate adaptive immunity against the cancer due to the release of intracellular materials containing HSPs complexed with tumor antigens. In this way yo T-cells, such as intraepithelial T-lymphocytes in the epithelium keep vigil for any transformation in neighboring cells or nascently transformed tumor cells, and efficiently eradicate them, completing the elimination phase of immuosurveillance mechanism. NK cells and/or NKT cells recognize HSP70 expressing tumor cells. CD3-NK cells have been found to recognize HSPs, and further recognition of HSPs expressing cells by lymphokine-activated killer cells (LAK cells) was also observed (42) . It clearly emphasizes the involvement of HSPs in activation and NK cell toxicity. The increased lysis may be correlated precisely with an increase of surface, but not intracellular, levels of HSP72 after heat shock. NK cells recognize particularly the part of HSP70 located at the carboxyl terminus of the HSP molecule, which is predicted to be extra cellular by the receptor recently recognized as CD94 (43) . As predicted, it would seem that HSP70 and HSP70-peptide (14-mer from C-terminus) have great specificity to CD94 present on NK cells, and the activation of NK cells is necessarily mediated by this receptor-ligand interaction. However, the involvement of any co-receptor for CD94 signaling has not yet been identified. This finding of NK cell activation by CD94 has been verified in several tumor cell types including carcinomas, sarcomas and leukemia (44) (45) (46) (47) . Furthermore, a signal peptide, derived from HSP60, has also been identified which binds to HLA-E and interferes with CD94INKG2A recognition, thereby enabling NK cells to detect stressed cells (48) . The activated NK cells release perforin as their effector function on stressed cells such as tumor cells, which cause their lysis. Perforin provided by NK cells in such a manner was found to be critical for NK and CTL expansion (49) . It has been found that perforin-deficient mice were unable to support CD8+CTL expansion by gp96, pointing to a role for cytotoxicity in the afferent arm of the Immune response.
Cancer immunotherapy with HSPs
For more than a decade, several efforts have been made to develop effective immunotherapy for cancer after the identification and isolation of several tumor markers. In this regard, many strategies have been devised to target and destroy tumors by eliciting effective anti-tumor immunity including cytokine therapy, active specific immunotherapy (vaccination) and adaptive immunotherapy (using tumor specific T cells or monoclonal antibodies). In the search for effective immunotherapy, several antigenic systems including irradiated tumor cells, tumor antigens (TAAs and TSTAs), peptides isolated from tumors and anti-idiotypic antibodies with various adjuvants have been administered for examination. Despite all these efforts, immunotherapy of cancer has not been considered perfect, though it has been found to increase the survival rate and life quality of cancer patients and open the possibility of further exploration in this regard.
It was observed that vaccination with tumorderived HSPs elicits a strong immunity against syngeneic tumors. This approach is based on the property of HSPs as chaperones which are found in association with several peptides in the biological system therefore reducing the possibility of tumor cells escaping from immunotherapy due to single antigen loss. By utilizing this approach, so far tumor immunity has been elicited in several types of malignancies.
HSPs loaded in vitro with synthetic peptides have been found to elicit specific CTL responses without any additional adjuvant (50) . This approach provides freedom to select specific peptides to design highly tailored and efficient HSP vaccines. Moreover, considering antigen escape as one of the major drawbacks of cancer immunotherapy, multiple peptides from different antigens can be selected and mixed to generate polyvalent vaccine in order to generate a more vigorous and diverse immune response. By using this approach it might be also possible to select a common pool of antigenic peptide expressed in a variety of tumors and to isolate and reconstitute them in vitro with HSPs in order to generate a broad spectrum cancer vaccine. Besides peptides, full-length proteins have also been utilized to generate HSP-based vaccines. In this approach, full-length well-known protein antigens were reconstituted in vitro with recombinant HSPs and used as a vaccine. It has slightly more advantage with the former in that it gives a variety of CTL epitopes in a single dose of protein, thus acting partially as polyvalent as well as targeting a specific tumor type.
HSP-based DNA vaccine has been brought about as a new approach to amalgamate the idea of gene therapy (51) . This approach uses HSPs in the form of chimeric DNA through the linkage of known antigen genes with HSPs. This chimeric HSP-antigen DNA can be introduced into the cellular genome of host-targeting, mainly to antigen presenting cells (APCs). This leads to the expression of tumor specific proteins in association with HSP that induces CTL responses through MHC 1. Vaccines containing human papilloma virus type 16E7 and HSP70 fusion genes resulted in preventive and therapeutic effects against an established tumor via CD8+ pathway after administration into human subjects (51) . This approach is beneficial in the sense that, without the involvement of any receptor (receptor mediated endocytosis), HSP fusion proteins are introduced into cellular machinery. Recently, immunization with HSP65/E7 fusion proteins was found to protect mice against challenge with a E7-expressing murine tumor cell line (TC-l cells), a cell line of cervical carcinoma (52) . These tumor-free animals are also protected against re-challenge or subsequent challenge with TC-l cells. In this connection, HSP-fusion genes have been shown very effective in eliciting strong CTL immune responses through the interaction of APCs. Therefore, the HSP DNA-antigen and HSP fusion proteins established themselves as a new and effective vaccine strategy against cancer.
Future prospects
The exciting results in the use of HSP-based vaccines against cancer have led to various clinical trials and development, and to date various approaches have been examined. Success in the pre-clinical studies in animal models led to phase I clinical trials of tumor-derived gp96 preparations as autologous tumor vaccines against renal cancer, melanoma (M.D. Anderson Cancer Center, Houston, TX), pancreatic cancer (Memorial Sloan Kettering Cancer Center, NY) and gastric cancer (University of Mainz, Germany) (53) . In preliminary clinical trials, HSP-based vaccine (in particular, HSP fusion proteins) shows very promising results in cancer immunotherapy (54) . For the complexity of the isolation of tumor antigenic peptides from tumor lysates, and freedom of selecting specific tumor antigenic peptides, several trials have been carried out to target and induce specific anti-tumor immunity by using HSP fusion proteins. More preclinical studies of HSP-fusion proteins in a variety of clinical settings are required to realize their excellent therapeutic potential. HSP fusion proteins, HSP E7 (fusion protein composed of HSP 65 from the bacterium Mycobacterium bovis BCG and the E7 protein from human papilloma, HPV type 16) are under clinical trial at the Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology (MIT) in collaboration with Stressgen Biotechnology Inc. HSP E7 has been found to be very effective in cancer types caused by HPV, such as cancer of the uterine cervix and head and neck cancer. These clinical trials give exciting data, which indicate their future in the immunotherapy of cancer. Since the immune system consists of several different interrelated, interdependent, interacting elements, a combinational therapy utilizing other approaches to immunomodulation together with HSP-based vaccination must be generated for efficient anti-tumor immunotherapy. Gene therapy of cancer utilizing HSP DNA tagged with antigenic DNA, and cell-based vaccines (e.g. DCs pulsed with HSP-antigen DNA chimera or DCs treated with HSP fusion proteins) may be powerful in treating cancer, and will be made more efficient by combining with hyperthermia which is reported to act as an adjuvant, stimulating extravasations of lymphocytes (55) and/or blockade of CTLA-4 antigen (cytolytic Tlymphocyte associated molecule-4, expressed on activated T-cells and results in T-cell anergy) (56) . The present review discusses our knowledge of the roles of HSPs in anti-tumor immunity and their uses in anti-tumor immunotherapy. Although studies have given very exciting results, this area of biomedical research is still in its infancy and many more new findings can be expected in the near future.
